首页> 外文会议>International Molecular Medicine Tri-Conference. >A Novel Small-Molecule IAP Antagonist, AZD5582, Draws Mcl-1 Down-Regulation for Induction of Apoptosis Through Targeting of cIAP1 and XIAP in Human Pancreatic Cancer
【24h】

A Novel Small-Molecule IAP Antagonist, AZD5582, Draws Mcl-1 Down-Regulation for Induction of Apoptosis Through Targeting of cIAP1 and XIAP in Human Pancreatic Cancer

机译:一种新型的小分子IAP拮抗剂AZD5582,通过靶向CIAP1和XIAP在人胰腺癌中诱导诱导细胞凋亡的MCL-1下调

获取原文

摘要

Inhibitor of apoptosis proteins (IAPs) plays an important role in controlling cancer cell survival. IAPs have therefore attracted considerable attention as potential targets in anticancer therapy. In this study, we investigated the anti-tumor effect of AZD5582, a novel small-molecule IAP inhibitor, in human pancreatic cancer cells. Treating human pancreatic cancer cells with AZD5582 differentially induced apoptosis, dependent on the expression of p-Akt and p-XIAP. Moreover, the knockdown of endogenous Akt or XIAP via RNA interference in pancreatic cancer cells, which are resistant to AZD5582, resulted in increased sensitivity to AZD5582, whereas ectopically expressing Akt or XIAP led to resistance to AZD5582.
机译:凋亡蛋白抑制剂(IAPS)在控制癌细胞存活方面发挥着重要作用。因此,IAPS引起了视为抗癌疗法潜在目标的显着关注。在这项研究中,我们研究了AZD5582,一种新型小分子IAP抑制剂在人胰腺癌细胞中的抗肿瘤作用。用AZD5582差异诱导的细胞凋亡治疗人胰腺癌细胞,取决于P-AKT和P-XIAP的表达。此外,通过RNA干扰抗胰腺癌细胞的内源AKT或XIAP的敲低导致AZD5582的敏感性增加,而强化表达AKT或XIAP导致抗AZD5582。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号